scholarly journals Parallel extreme gradient boosting classifier for lung cancer detection

Author(s):  
Rana Dhia’a Abdualjabar ◽  
Osama A. Awad

Most lung cancers do not cause symptoms until the disease is in its later stage. That led the lung cancer having a high fatality rate compared to other cancer types. Many scientists try to use artificial intelligence algorithms to produce accurate lung cancer detection. This paper used extreme gradient boosting (XGBoost) models as a base model for its effectiveness. It enhanced lung cancer detection performance by suggesting three stages model; feature stage, XGBooste parallel stage and selection stage. This study used two types of gene expression datasets; RNA-sequence and microarray profiles. The results presented the effectiveness of the proposed model, especially in dealing with imbalanced datasets, by having 100% each of sensitivity, specificity, precision, F1_score, area under curve (AUC), and accuracy metrics when it applied on all of the datasets used in this study.

Lung cancer is more dangerous than any other cancer. Nowadays many people are affecting lung cancer because of their lifestyle and environmental conditions. The basic cause of lung cancer is smoking. Many steps are taken to avoid smoking but on the other way the cancer is affecting the people. In this paper, the Enhanced Deep Learning (EDL) based algorithm is introduced to detects cancer in lungs in various patients based on their symptoms. It is very important to detect the cancer in the earliers stages. The proposed system calculates the three parameters such as sensitivity, specificity and accuracy. Results show the performance of the proposed system.


2021 ◽  
Author(s):  
Moslem Bahadori ◽  
Shahriar Dabiri ◽  
Mohammad Hossein Azizi ◽  
Neda Bahadori

The emergence of patient-tailored medicine has changed all measurable disease outcomes. Among human diseases, cancers appear to be the most dangerous. Furthermore, lung cancers rank the first among human cancers in both morbidity and mortality. When lung cancer is clinically diagnosed, it is often too late for therapy. The absence of accurate and specific tools for early detection results in a poor prognosis for lung cancer. The discovery of microRNAs and their function in lung cancer offers a new mechanism for the detection of lung cancer cells. These molecules, derived from cancerous cells, circulate in the patient's blood. Recently, a revolutionary technique, i.e., liquid biopsy has shown promise in discovering these circulating microRNAs molecules in body fluids, namely peripheral blood. A liquid biopsy allows the detection and isolation of circulating tumor cells, circulating nucleotides, and cellular exosome as a source of genomic and proteomic information in cancerous patients, especially in the early stages of cancer cell development. In this review, by searching various databases, including PubMed, Google Scholar, and Scopus, we explore liquid biopsy as a novel tool and the application of miRNAs in lung cancer detection in diagnostic pathology.  


Lung cancer is the foremost cause of cancer-related deaths world-wide [1]. It affects 100,000 Americans of the smoking population every year of all age groups, particularly those above 50 years of the smoking population [2]. In India, 51,000 lung cancer deaths were reported in 2012, which include 41,000 men and 10,000 women [3]. It is the leading cause of cancer deaths in men; however, in women, it ranked ninth among all cancerous deaths [4]. It is possible to detect the lung cancer at a very early stage, providing a much higher chance of survival for the patients.


Sign in / Sign up

Export Citation Format

Share Document